共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting显示文摘Diffuse large B-cell lymphoma(DLBCL)is the most common non-Hodgkin’s lymphoma(NHL)and has high heterogeneity.Approximately 30%–50%of patients develop relapsed/refractory(R/R)disease,which remains a major cause of mortality1-3.In recent years,a variety of novel therapies have emerged,including bispecific T-cell engagers(BiTEs),antibody–drug conjugates(ADCs),chimeric antigen receptor T cells(CAR-T),and selective BTK inhibitors,which have provided effective treatment strategies for patients with DLBCL1,4.Recently,the 58th Annual Meeting of the American Society of Clinical Oncology(ASCO)was held in Chicago,presenting cutting-edge studies in DLBCL.Here,we discuss a selection of interesting data on this topic. | Minghan Qiu Shan Wu Xinrui Chen Huaqing Wang | 2022 | Cancer Biology & Medicine2022，19，8： | 0 |
| 2 | Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγproduction显示文摘Adoptive cell transfer(ACT)using chimeric antigen receptor(CAR)modified T cells and T cell receptor(TCR)engineered T cells has shown therapeutic efficacy in cancer treatment1,2.CAR T cells are widely applicable to tumor patients because of their ability to directly identify tumor cells in an MHCindependent manner. | Yelei Guo Chuan Tong Zhiqiang Wu Yuting Lu Yao Wang Weidong Han | 2023 | Cancer Biology & Medicine2023，20，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员